LEADER 01735nam  2200421Ia 450 
001 9910696397103321
005 20071217144452.0
035   $a(CKB)5470000002376856
035   $a(OCoLC)184738729
035   $a(EXLCZ)995470000002376856
100   $a20071217d2007      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug safety$b[electronic resource] $epreliminary findings suggest weaknesses in FDA's program for inspecting foreign drug manufacturers : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives /$fstatement of Marcia Crosse
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2007]
215   $a24 pages $cdigital, PDF file
225 1 $aTestimony ;$vGAO-08-224 T
300   $aTitle from title screen (viewed on Dec. 12, 2007).
300   $a"For release ... November 1, 2007."
300   $aPaper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aDrug safety 
606   $aDrugs$xSafety measures
606   $aDrugs$xInspection
615  0$aDrugs$xSafety measures.
615  0$aDrugs$xInspection.
700   $aCrosse$b Marcia$01380679
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Energy and Commerce.$bSubcommittee on Oversight and Investigations.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696397103321
996   $aDrug safety$93449630
997   $aUNINA